Keywords: icn, pharma, earnings, take, downturn, pharmaceuticals, posted
ICN Pharma earnings take a downturn
Article | 03 August 2001
ICN Pharmaceuticals has posted second-quarter 2001 revenues of $206million, up 7% on the like, year-earlier period, while net income fell 32.3% to $21.3 million ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- US FDA advisory panel backs approval of Merck & Co's suvorexant, but only at lower doses
- Italy's pharma market slump set to continue, warns GlobalData
- Is failure to adopt business process management putting the pharma industry at risk?
